Attention Investors: Edelson Lechtzin LLP Launches Investigation into Securities Fraud Claims Against Eiger Biopharmaceuticals Inc. (NASDAQ: EIGR) Shareholders
Investigation into Securities Fraud Claims on Behalf of Eiger BioPharmaceuticals Newtown, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) The law firm of Edelson Lechtzin LLP is investigating securities fraud claims on behalf of all purchasers of Eiger BioPharmaceuticals, Inc. (“Eiger”) (NASDAQ: EIGR) common stock. Investors who purchased Eiger common stock between March 10, 2021 and October…